Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Proteonomix, a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, has established a wholly-owned subsidiary StromaCel to develop therapies using stromal cells.
Subscribe to our email newsletter
StromaCel is the fifth subsidiary of Proteonomix, whose operating subsidiary is National Stem Cell. Its subsidiary is The Sperm Bank of New York, which is engaged in reproductive tissue banking, including sperm, ova, ovarian tissue and testicular tissue.
The mission of StromaCel is to develop therapies using stromal cells. Stromal cells are key components of tissues and provide critical cytokines and growth factors as well as the cellular microenvironment for normal homeostasis. StromaCel’s goal is to study the basic cellular properties of stromal cells and to identify the utility of cellular and protein derivatives in disease repair.
Proteonomix Regenerative Translational Medicine Institute aims to concentrate on the translation of research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. The company plans to establish a subsidiary to each of its technologies. Proteonomix has facilities at a number of academic institutions.